Company Overview and News

1
TCON / TRACON Pharmaceuticals, Inc. 424B3 (Prospectus)

12h sec.gov
tcon-424b3.htm Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-224809

3
TCON / TRACON Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-05-10 sec.gov
tcon-10q_20180331.htm UNITED STATES

4
TCON / TRACON Pharmaceuticals, Inc. FORM S-3

2018-05-10 sec.gov
tcon-8k_20180509.htm

 
TRACON Pharmaceuticals' (TCON) CEO Charles Theuer on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals First Quarter 2018 Earnings Conference Call. At this time, all callers are in a listen-only mode. After the speakers’ prepared remarks, we will conduct a question-and-answer session and instructions will be given at that time.

 
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-05-09 sec.gov
tcon-8k_20180509.htm

1
BRIEF-Tracon Pharmaceuticals Says Patricia Bitar Notified That Resigning As Co's CFO

2018-05-04 reuters
* TRACON PHARMACEUTICALS INC - ON APRIL 30, PATRICIA L. BITAR NOTIFIED THAT RESIGNING AS CO'S CFO, EFFECTIVE JUNE 15, 2018- SEC FILING Source text for Eikon: (bit.ly/2w9w9yD) Further company coverage:

2
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-05-04 sec.gov
tcon-8k_20180430.htm

2
TCON / TRACON Pharmaceuticals, Inc. DEF 14A

2018-04-25 sec.gov
tcon-def14a_20180613.DOCX.htm UNITED STATES

6
TCON / TRACON Pharmaceuticals, Inc. DEFA14A

2018-04-25 sec.gov
tcon-defa14a_20171231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-04-23 sec.gov
tcon-8k_20180423.htm

4
TCON / TRACON Pharmaceuticals, Inc. / Puissance Cross-border Opportunities V Llc - null (Activist Investment)

2018-04-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tracon Pharmaceuticals, Inc. ________________________________________________________________________________________________________________________________

1
TCON / TRACON Pharmaceuticals, Inc. / Puissance Cross-border Opportunities V Llc - null (Activist Investment)

2018-04-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tracon Pharmaceuticals, Inc. ________________________________________________________________________________________________________________________________

3
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-04-10 sec.gov
tcon-8k_20180406.htm

1
TCON / TRACON Pharmaceuticals, Inc. / Puissance Cross-border Opportunities V Llc - SCHEDULE 13D (Activist Investment)

2018-04-06 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Tracon Pharmaceuticals, Inc. (Name of Issuer)

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

16h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 89237H100